Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle Solution

NCT05914805 is registered in ClinicalTrials.gov with Cassiopea SpA as lead sponsor.

NCT NCT05914805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05914805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle Solution
Lead sponsor
Cassiopea SpA
Phase
Phase 3
Overall status
Completed
Start date
August 17, 2023
Completion date
July 16, 2025
Enrollment
762 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia, androgenetic